lisene, the precise populations that may choose gingko
selhpresctiption may sho he chase more at risk of potential
inceractions because of their use of prescription deugs
aifecting hemostasis. (See further discussion later in the
sections an interactions involing: antiplatelet agents and
A numnber of the beneficial interactions of ginkgo listed Laer
relate to its antidschemic, antioxidant, neuroprotective eure
reparative, and chemoprotective effects, Typically, these inter
actions involve reduction af drg-indaved tonite, saab as
eplirorosicty oF neurotoxicity, Uhrougls multiple mechanisins,
these provectve effects against dug toxicities most likely
apply fo numerons medications other thant those For whieh
preliminary evidence already exists; see doxorubicin, evcospar.
ine, gentamicin, and haloperidol later. Integrative oncological
appliations for ginkgo may include radiation sensitization as
Well as chemoprotection.* The role of ginkgo extract in
integrative oncolopical protocols isa new area of stady
Pharmacol
‘There are some pharmacokinetic dats on ginkgo extracts in
both animal mols ard humans, Bieavalabilay oF both the
triterpene Factones and faveriol glycosides i igh, with Figures
tp to eighey per sent for some ginkgolide fract
nol glcosiles are rapidly absorbed, but are extsmstvely meta
bolized in humans, whikt the ‘terpenoic are exerted
1 halflife of about six hours?
rinchanged, with ove
“There is animal and human evidence that the extract constitu:
cn can crus the Hocsl-tra barccee™ 2 The pinkpo Bevo
holds querciis, kaeinplvol, sad Horhamaetin are themelves
substrates of P-glycoprotein (P-gp).
fea on Dug Memduin anf Biahity
ly sect drug: metabolizing systems had not been
systematically investigated. Thikial data fkom in itso studies
was sypisaly inconclusive or conilisting, but results of more
recent in vivo human wiak new suggest minimal effects of
the heth on oytoclirome D430 (CYPS0) activin
Gurley ct al studied the